Anti-CD123 CAR T cell therapy (Shanghai Hrain Biotechnology)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD123 CAR T cell therapy (Shanghai Hrain Biotechnology)

Drug Alias NameCD123CAR-41BB-CD3zeta-EGFRt

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionInterleukin 3 receptor modulators

TargetsInterleukin 3 receptor

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesHrain Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHrain Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A